Coultreon Biopharma, a Galapagos-acquired spinout focused on immunology, raised $125 million in a Series A to advance a small-molecule SIK3 inhibitor program. The company plans Phase 2 studies in psoriasis and ulcerative colitis, positioning the strategy as an oral alternative intended to replicate or compete with the effectiveness of injectable biologics. The funding supports clinical execution and further development of Coultreon’s pipeline concept around selectively inhibiting SIK3, a target framed as a novel immunology node. The deal also signals continued investor appetite for orally delivered immunotherapies that can compete in chronic inflammatory indications. Coultreon’s earlier acquisition from Galapagos underlines how platform and target assets continue to move from large pharma into focused clinical-stage structures.